Director, RaaS Research Group, Research as a Service (RaaS)

RaaS Research Group (RaaS)

Director, RaaS Research Group

Insightful Financial Models and Research Analysis

Research as a Service (RaaS)

Connect to the right investors through smart and insightful financial models and research analysis.

Equity Bottom-Up

EMvision Medical Devices Ltd / Equity Bottom-Up

<div>
<table class="table table-striped">
<tbody>
<tr>
<td>
<div>
<p><a target="_blank"></a><a target="_blank"></a><a target="_blank"></a><a target="_blank"></a><a target="_blank"></a><a target="_blank"></a><a target="_blank"></a><a target="_blank"></a><a target="_blank"></a><a target="_blank"></a><a target="_blank">EMVision Medical Devices Ltd (ASX:EMV) is developing a portable brain scanner for rapid, point-of-care stroke diagnosis and monitoring. The technology uses electromagnetic microwave imaging, the technology developed over 10-years by researchers at the University of Queensland, and potentially offers portability and affordability advantages over the current standard of care cost (MRI/CT scans). EMV listed on the ASX in November 2018, raising $6m at an issue price of $0.25/share. It raised a further $4.5m at $0.85/share in November 2019 and $9m at $1.42/share in July 2020.&nbsp; EMV has conducted a single study with 30 stroke patients receiving both the EMV scan and either an MRI and/or CT scan. The EMV scan was able to identify the type of stroke with an accuracy of 93.3%-96.0% and localise the correct quadrant with an overall accuracy of 86.7%-96.0%. The FDA has recommended the De Novo pathway for the product, designed for low-medium risk, first-of-a-kind products.&nbsp; EMV will engage with the FDA to confirm the required evidence the clinical trial performance data required. assuming and incorporating a pivotal clinical trial with the end design being finalised. The group ended December 2020 with net cash of $13.0m and in March 2020, in collaboration with the Australian Stroke Alliance, was the recipient of a Medical Research Future Fund Frontiers grant which delivers $8m in non-dilutive cash funding towards EMVision’s product development and clinical validation for hospital and pre-hospital models. </a></p>
</div>
</td>
</tr>
</tbody>
</table>
</div>







EMVision Medical Devices Ltd (ASX:EMV) is developing a portable brain scanner for rapid, point-of-care stroke diagnosis and monitoring. The technology uses electromagnetic microwave imaging, the technology developed over 10-years by researchers at the University of Queensland, and potentially offers portability and affordability advantages over the current standard of care cost (MRI/CT scans). EMV listed on the ASX in November 2018, raising $6m at an issue price of $0.25/share. It raised a further $4.5m at $0.85/share in November 2019 and $9m at $1.42/share in July 2020.&nbsp; EMV has conducted a single study with 30 stroke patients receiving both the EMV scan and either an MRI and/or CT scan. The EMV scan was able to identify the type of stroke with an accuracy of 93.3%-96.0% and localise the correct quadrant with an overall accuracy of 86.7%-96.0%. The FDA has recommended the De Novo pathway for the product, designed for low-medium risk, first-of-a-kind products.&nbsp; EMV will engage with the FDA to confirm the required evidence the clinical trial performance data required. assuming and incorporating a pivotal clinical trial with the end design being finalised. The group ended December 2020 with net cash of $13.0m and in March 2020, in collaboration with the Australian Stroke Alliance, was the recipient of a Medical Research Future Fund Frontiers grant which delivers $8m in non-dilutive cash funding towards EMVision’s product development and clinical validation for hospital and pre-hospital models. 







EMVision Medical Devices (EMV) - Portability and Affordability for Brain Scans

Australia

Emvision Medical Devices Ltd provides healthcare testing services. The Company offers medical imaging for brain and other organs. Emvision Medical Devices serves customers in Australia.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

EMvision Medical Devices Ltd (EMV AU)

EMVision Medical Devices (EMV) - Portability and Affordability for Brain Scans

EMVision Medical Devices Ltd (ASX:EMV) is developing a portable brain scanner for rapid, point-of-care stroke diagnosis and monitoring. The...

Research as a Service (RaaS)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)